De Quervain's thyroiditis classification

Revision as of 21:13, 29 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

De Quervain's thyroiditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating De Quervain's thyroiditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]

Overview

De Quervain's thyroiditis can be classified according to the development of symptoms into the prodromal stage, hyperthyroid stage, euthyroid stage, and hypothyroid stage.

Classification

De Quervain's thyroiditis can be classified according to the development of symptoms into the following stages:[1][2][3]

Prodromal stage

The prodromal stage includes low-grade fever and viral flu-like symptoms, such as sore throat, myalgia, arthralgia, and malaise.

Hyperthyroid stage

It follows the prodromal stage and includes the symptoms of thyrotoxicosis.

Euthyroid stage

Thyroid hormones are within the normal range and there are no specific symptoms.

Hypothyroid stage

Thyroid hormones are decreased as a result of glandular damage.

References

  1. "Thyroiditis — NEJM".
  2. Engkakul P, Mahachoklertwattana P, Poomthavorn P (2011). "Eponym : de Quervain thyroiditis". Eur. J. Pediatr. 170 (4): 427–31. doi:10.1007/s00431-010-1306-4. PMID 20886353.
  3. Leibovitch G, Maaravi Y, Shalev O (1989). "Severe facial oedema and glossitis associated with mianserin". Lancet. 2 (8667): 871–2. PMID 2571803.